Your Chief AI Officer · Monday, November 2, 2026 · Act today
Medicare's AI-enabled prior authorization pilot linked to nearly 20% drop in some services
Study2 sourcesFor patients and employees
A research letter published Oct. 26 in JAMA found that in the first six months of Medicare's Wasteful and Inappropriate Service Reduction (WISeR) pilot, use of targeted services fell in participating states relative to the rest of the country. Researchers from the University of Minnesota School of Public Health and Brown University reported a drop of nearly 20% in some services, as covered by Becker's Hospital Review and Becker's Payer Issues.
A research letter published Oct. 26 in JAMA offers the first outside measurement of Medicare's Wasteful and Inappropriate Service Reduction (WISeR) pilot, which brings AI-enabled prior authorization to traditional Medicare across six states over six years, according to CMS. Researchers from the University of Minnesota School of Public Health and Brown University School of Public Health found that in the pilot's first six months, use of targeted services fell in participating states relative to the rest of the country, as reported by Becker's Hospital Review.
The numbers are specific. Compared with trends in other states, monthly epidural steroid injections declined 15%, and other targeted services declined nearly 20%, per Becker's Payer Issues. The effect was strongest right after launch. For epidural steroid injections, the reduction was roughly 21% in the first quarter of 2026 and about 9% in the second. For the other services it moved from 21% to 18% between quarters. Services with delayed WISeR implementation served as a negative control and showed no significant change, which strengthens the link to the pilot itself.
What the evidence does not show is just as important. Lead author Hannah Neprash, PhD, said the key question that cannot yet be answered is "whether the care not received was wasteful or necessary," according to Becker's Hospital Review. This is a six-month research letter on utilization, not a study of patient outcomes. The pilot has drawn pushback but is continuing.
For finance and revenue cycle leaders, a sustained relative drop of this size in targeted services is a revenue planning input, and the fading effect for injections suggests volumes may partly recover as practices adapt to the process. For chief medical officers, the open question about necessary versus avoidable care is one your own clinical data can help answer for your patients. For operations and AI leaders, the pattern points to front-loaded friction: the first quarter is where staffing, documentation and submission workflows matter most.
The move: pull your own volume, authorization and denial data for WISeR-targeted services in participating states, set it against the JAMA findings quarter by quarter, and track which deferred patients later returned or escalated. Bring that analysis to your next payer review. It turns a national average into evidence about your patients, your clinicians' time and your revenue.
Do this week. Pull your own volume and authorization data for WISeR-targeted services in participating states and compare it with the JAMA findings before your next payer review.
Run this
The prompt to act on this item, for your own model.
Paste it into Claude, ChatGPT or Copilot and fill the bracketed slots with your own numbers. The output is a draft for your team to check, built only from the sources on this page. Never paste patient data. How these prompts are written.
You are a revenue cycle and finance advisor to the executive team of [your organization], which delivers services targeted by Medicare's WISeR pilot. Context: A research letter published Oct. 26 in JAMA, by researchers from the University of Minnesota School of Public Health and Brown University School of Public Health, measured the first six months of Medicare's Wasteful and Inappropriate Service Reduction (WISeR) pilot. The pilot brings AI-enabled prior authorization to traditional Medicare across six states over six years, according to CMS. As reported by Becker's Hospital Review and Becker's Payer Issues, compared with trends in other states, monthly epidural steroid injections declined 15% and other targeted services declined nearly 20%. For epidural steroid injections the reduction was roughly 21% in the first quarter of 2026 and about 9% in the second. For other services it moved from 21% to 18%. Services with delayed WISeR implementation showed no significant change. Lead author Hannah Neprash said the open question is "whether the care not received was wasteful or necessary." This is a utilization study, not a study of patient outcomes. Task: Compare our aggregate data for WISeR-targeted services against the JAMA findings, quarter by quarter, before our next payer review on [date of next payer review]. Our data: participating states where we operate [states]; targeted services we deliver [list of services]; monthly volumes before and after launch [aggregate monthly volumes]; authorization approvals and denials [aggregate counts]; deferred cases that later returned or escalated [aggregate count]. Output: a one-page memo for the executive team with these sections: Summary, How our trend compares, What the data cannot tell us, Revenue planning implications, Questions for the payer review, Items to verify. Guardrails: Use only the facts above and the slots I fill. Cite Becker's Hospital Review, Becker's Payer Issues and the JAMA research letter by name. Flag anything uncertain or that needs verifying, including any gaps in our data. Use aggregate figures only and no patient data. Nothing here is medical advice. Mark the memo as a draft for the team to check.
- The evidence.
- The JAMA research letter, as reported by Becker's, links the pilot to a nearly 20% relative drop in use of some targeted services over its first six months.
By seat
For the Chief AI Officer. Brief the board that AI-enabled prior authorization now has a measured effect on service volume and add WISeR exposure to the AI risk register.
For the CFO and revenue cycle. Model the revenue effect of a relative volume drop on WISeR-targeted services in participating states and adjust forecasts.
For the Chief Medical Officer and physicians. Ask physician leaders to review whether care in targeted services is being delayed or forgone and document clinical rationale for appeals.
Checked before publishing. 2 independent outlets. 1 figure matched to the source text.
Sources
- Becker's Hospital Review, Medicare’s AI-enabled prior authorization pilot linked to nearly 20% drop in some services
- Becker's Payer Issues, Medicare’s AI-enabled prior authorization pilot linked to nearly 20% drop in some services
Drafted by Lumen from the sources above, scored by a second pass on six criteria, then checked by rule against those sources (every figure, two independent outlets or a primary source) and published only when it passes. A person can pull any item, and corrections are published here. Apolitical, always. Nothing here is medical advice. How Your Chief AI Officer is made.
Also in this brief